Chonluten — Khavinson bioregulator — bronchial / pulmonary
Chonluten (AEDG sequence, same as Epithalon structurally but bronchial origin) targets lung tissue. In vitro THP-1 monocyte study: inhibited TNF and IL-6 production in LPS-stimulated cells, increased tyrosine phosphorylation of mitogen-activated kinases. Clinical study (n=47, chronic bronchitis with asthmatic component): 82% of patients showed improved health status, reduced coughing, decreased sputum, and disappearance of wheezing.
Overview
This page is part of Hormonaly's evidence-graded compound library. All clinical claims are linked to peer-reviewed sources via our dual-layer citation verification pipeline.
Compound Class
Khavinson bioregulator — bronchial / pulmonary
Mechanism of Action
Chonluten (AEDG sequence, same as Epithalon structurally but bronchial origin) targets lung tissue. In vitro THP-1 monocyte study: inhibited TNF and IL-6 production in LPS-stimulated cells, increased tyrosine phosphorylation of mitogen-activated kinases. Clinical study (n=47, chronic bronchitis with asthmatic component): 82% of patients showed improved health status, reduced coughing, decreased sputum, and disappearance of wheezing.
Regulatory Status
Not FDA approved. Registered pharmaceutical in Russia.
Evidence Level
Low — in vitro data + n=47 small clinical study. Registered pharmaceutical in Russia (Chonluten oral capsules).